In addition, EGFR amplification is more prevalent in IDH-wildtype diffuse gliomas (66.0%) and GBM (85.5%) [28], which are also associated with poorer prognostic factors, consistent with our findings. The gene discussed is IDH1; the disease is glioblastoma.